Nicoletta Vivona
University of Palermo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nicoletta Vivona.
European Journal of Epidemiology | 2001
C.M. Barbagallo; F. Polizzi; Severino M; Manfredi Rizzo; Nicoletta Vivona; Francesco Onorato; Rosalia Caldarella; A.B. Cefalù; Davide Noto; Alberto Notarbartolo; Maurizio Averna
Polymorphisms of apoE gene are able to modulate lipoprotein metabolism at different steps and to influence LDL-cholesterol (LDL-C) levels and also other lipoproteins features. Population studies documented large differences in the frequency of apoE alleles which could be even related to the prevalence of cardiovascular disease. In this study we evaluated the apoE genotypes and allele frequency in 576 subjects living in a small island in the Tyrrhenian Sea and the relative contribution of apoE polymorphism on plasma lipid and lipoprotein profile, including LDL particle size. We found a cumulative frequency of 0.073, 0.866 and 0.061 for ε2, ε3 and ε4 alleles respectively. Moreover ε3 subjects had only triglyceride levels significantly lower and LDL-C and lipoprotein (a) (Lp(a)) levels higher than ε2 carriers. LDL-particle size was significant smaller in ε2 subjects than both ε3 and ε4 carriers, but the difference disappeared when data were adjusted for triglycerides. In conclusion we have provided further evidence of a low prevalence of ε4 allele in a Mediterranean population which may represent a genetic protective factor of these populations. Environmental factors, such as diet, occurring in this area may have attenuated the influence of this gene on plasma lipoproteins.
Clinical Biochemistry | 2009
Nicoletta Vivona; Giulia Bivona; Davide Noto; Bruna Lo Sasso; Angelo B. Cefalù; Gaia Chiarello; A Falletta; Marcello Ciaccio; Maurizio Averna
OBJECTIVES One third to one half of the variation in vascular disease occurrence remains unexplained by traditional risk factors. Since atherosclerosis may, in part, be an inflammatory disease, circulating factors related to inflammation may be predictors of cardiovascular disease. The aim of this study was to evaluate the association between common atherosclerotic risk factors and markers of inflammation. DESIGN AND METHODS Serum levels of soluble CD40 (sCD40L), high-sensitive C-reactive protein (hs-CRP) and homocysteine (Hcy) were measured in 251 patients selected from a series of 438 subjects affected by previous myocardial infarction, angina or other cardiovascular diseases. RESULTS sCD40L levels were lower in patients with previous myocardial infarction while no association was observed between sCD40L and Hcy levels and other risk factors. Only hs-CRP levels positively correlated with increased number of risk factors. CONCLUSION In a setting of patients affected with coronary artery disease no association between sCD40L and homocysteine levels and atherosclerotic risk factors was observed; only hs-CRP showed increased levels according to the number of risk factors. Future studies using larger cohorts will be needed to validate the clinical use of markers of inflammation in the prediction of cardiovascular events.
Omics A Journal of Integrative Biology | 2011
Monica Notarbartolo; Lydia Giannitrapani; Nicoletta Vivona; Paola Poma; Manuela Labbozzetta; Ada Maria Florena; Rossana Porcasi; Vito Michele Rosario Muggeo; Luigi Sandonato; Melchiorre Cervello; Giuseppe Montalto; Natale D'Alessandro
The transcription factor Yin Yang 1 (YY1) can favor several aspects of tumorigenesis. In turn, Raf-1 Kinase Inhibitor Protein (RKIP) inhibits the oncogenic activities of MAPK and NF-κB pathways and promotes drug-induced apoptosis. Mutual influences between YY1 and RKIP may exist, and there are already separate evidences that relevant increases in YY1 and reductions in RKIP occur in hepatocellular carcinoma (HCC). However, the levels of the two factors have never been concomitantly examined in HCC. We evaluated by RT-PCR the mRNA levels of YY1, YY1AP, RKIP, and survivin in 35 clinical HCCs (91% HCV-related), in their adjacent cirrhotic tissues and in 6 healthy livers. Immunohistochemical analyses were also performed. The ratio of YY1 to RKIP mRNA was constantly profoundly inverted in the tumors compared with the adjacent nontumoral tissues. A similar result occurred frequently at protein level. Hyperactivation of YY1 in tumors was corroborated by its nuclear localization and the finding that in the tumors there were also increases in YY1AP, a YY1 coactivator not expressed in normal liver, and in survivin, as a possible target of YY1. The frequent alteration in the YY1-RKIP balance might represent a marker of malignant progression and be exploited for therapeutic interventions in HCC.
Nutrition Metabolism and Cardiovascular Diseases | 2009
Davide Noto; A.B. Cefalù; C.M. Barbagallo; Michelangelo Sapienza; Giovanni Cavera; Nardi I; Michele Pagano; Nicoletta Vivona; Alberto Notarbartolo; Maurizio Averna
BACKGROUND AND AIMS Epidemiological prospective data on cardiovascular (CV) events in elderly subjects from Mediterranean populations are lacking. We aimed to investigate 15-year incidence of CV events and to evaluate the association with CV risk factors in an elderly Mediterranean population. METHODS AND RESULTS The population of a small Sicilian village were enrolled, visited and a blood sample was drawn at baseline. CV events were recorded in the 15 years of follow-up. From 1351 subjects (75% of the resident population); 315 were in the age range 65-85 years; 266 subjects free from CV disease were analysed. Seventy-seven CV events were recorded in 73 out of 266 subjects, with a 19.7% rate (in 10 years). Hypertension (HTN) (hazards ratio=2.1) and diabetes mellitus (DM) (hazards ratio=1.8) were independently associated with CV events. Subjects with both DM and HTN showed a lower survival free of CV events compared to those with DM or HTN. CONCLUSIONS In a 15-year follow-up of an elderly Mediterranean population free from CV disease, diabetes mellitus and hypertension were related to CV events. The control of risk factors in the elderly needs to be reinforced to achieve better results in terms of CV prevention.
Nutrition Metabolism and Cardiovascular Diseases | 2003
M. Rolleri; Nicoletta Vivona; Giovanni Emmanuele; A.B. Cefalù; Livia Pisciotta; V. Guido; Davide Noto; B. Fiore; C.M. Barbagallo; Alberto Notarbartolo; Salvatore Travali; Stefano Bertolini; Maurizio Averna
BACKGROUND AND AIMS Type III hyperlipoproteinemia, or dysbetalipoproteinemia, is commonly associated with apolipoprotein E2 homozygosity (Cys112, Cys158). Apo E2-Christchurch (Arg136-->Ser), a rare mutation of the Apo E gene, located in the receptor-binding domain of the protein, has been found to be associated in the vast majority of cases of dysbetalipoproteinemia. METHODS AND RESULTS This is the first report of two Italian kindreds carrying the Arg136-->Ser mutation. One family is a four-generation kindred from Genoa (Liguria, Italy) with a high rate of mortality due to coronary artery disease: the proband was a 51-year-old woman with previous myocardial infarction and residual angina, severe carotid atherosclerosis, peripheral arterial vascular disease and arterial hypertension. The other family was identified in Palermo (Sicily, Italy): the proband was an overweight 62-year-old man with a mixed form of hyperlipidemia. The mutation, which was identified by means of Apo E genotyping followed by direct sequencing, co-segregated with the same haplotype in the two families. CONCLUSIONS The family histories and clinical examinations of these subjects clearly show that the Apo E Arg136-->Ser variant fully expresses a type III phenotype in association with a second allele coding for Apo E2, and only partially in association with a second allele coding for Apo E4.
Omics A Journal of Integrative Biology | 2012
Paola Poma; Manuela Labbozzetta; Nicoletta Vivona; Rossana Porcasi; Natale D'Alessandro; Monica Notarbartolo
Oncology Letters | 2015
Manuela Labbozzetta; Paola Poma; Nicoletta Vivona; Alessandro Gulino; Natale D'Alessandro; Monica Notarbartolo
Nutrition Metabolism and Cardiovascular Diseases | 2001
A.B. Cefalù; Giovanni Emmanuele; Giuseppina Marino; B. Fiore; Rosalia Caldarella; Nicoletta Vivona; Davide Noto; C.M. Barbagallo; Salvatore Costa; Maria Concetta Gueli; Stefano Bertolini; Notarbartolo A; Salvatore Travali; Maurizio Averna
Forum on Immunopathological Diseases and Therapeutics | 2014
Natale D'Alessandro; Manuela Labbozzetta; Nicoletta Vivona; Monica Notarbartolo Di Villarosa; Paola Poma; Monica Notarbartolo
Archive | 2013
Natale D'Alessandro; Manuela Labbozzetta; Nicoletta Vivona; Monica Notarbartolo Di Villarosa; Paola Poma